BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8757502)

  • 1. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.
    Hallek M; Danhauser-Riedl S; Herbst R; Warmuth M; Winkler A; Kolb HJ; Druker B; Griffin JD; Emmerich B; Ullrich A
    Br J Haematol; 1996 Jul; 94(1):5-16. PubMed ID: 8757502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
    Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
    Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway.
    Tauchi T; Boswell HS; Leibowitz D; Broxmeyer HE
    J Exp Med; 1994 Jan; 179(1):167-75. PubMed ID: 7505797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
    Wisniewski D; Lambek CL; Liu C; Strife A; Veach DR; Nagar B; Young MA; Schindler T; Bornmann WG; Bertino JR; Kuriyan J; Clarkson B
    Cancer Res; 2002 Aug; 62(15):4244-55. PubMed ID: 12154026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
    Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
    Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jak2 is involved in c-Myc induction by Bcr-Abl.
    Xie S; Lin H; Sun T; Arlinghaus RB
    Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New understanding of the pathogenesis of CML: a prototype of early neoplasia.
    Clarkson BD; Strife A; Wisniewski D; Lambek C; Carpino N
    Leukemia; 1997 Sep; 11(9):1404-28. PubMed ID: 9305592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
    Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
    J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
    Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
    Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
    Wisniewski D; Strife A; Berman E; Clarkson B
    Leukemia; 1996 Feb; 10(2):229-37. PubMed ID: 8637231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.
    Schwartz GN; Liu YQ; Tisdale J; Walshe K; Fowler D; Gress R; Bergan RC
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):329-39. PubMed ID: 9743470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl.
    Laneuville P; Sun G; Timm M; Vekemans M
    Blood; 1992 Oct; 80(7):1788-97. PubMed ID: 1327283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes.
    Ernst TJ; Slattery KE; Griffin JD
    J Biol Chem; 1994 Feb; 269(8):5764-9. PubMed ID: 8119916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.